These results were partially consistent with the study by Weberpals, et al. (22) who found that CVD risk was not relevant to the HER2 status and hormone receptor subtypes among breast cancer patients with chemotherapy or radiotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.